Back to News
Market Impact: 0.35
Alebund Pharmaceuticals Receives FDA IND Clearance For AP308 In IgA Nephropathy
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Alebund Pharmaceuticals (09637.HK) received FDA clearance for the IND application for AP308, an engineered recombinant IgA protease for IgA nephropathy. The clearance enables the company to begin U.S. clinical development of the investigational therapy, representing a meaningful regulatory and pipeline milestone.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- J&J prostate cancer drug shows promising tumor responses in early trial
- Piero Cipollone: Interview with Milano Finanza
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs
- AI Tools for CFA Charterholders: An Evidence Standard